Welcome to the NCRI CTRad newsfeed. Subscribe to hear these news and announcements as they happen.
Dr Iain Frame appointed NCRI CEO
NCRI are pleased to announce the appointment of Dr Iain Frame as the new NCRI CEO. You can read more below:
» Dr Iain Frame appointed NCRI CEO (NCRI webpage)
NCRI case study: find out how CTRad is changing practice through a portfolio of innovative and collaborative clinical trials
NCRI's case study describes what CTRad is doing in non-small cell lung cancer to change practice through a portfolio of innovative and collaborative clinical trials
» Developing better cancer trials for non-small cell lung cancers (NCRI webpage)
NCRI blog post: latest CTRad progress
NCRI's blog post looks at some of the progress that CTRad has made and its strategy for impact in the future.
» CTRad: moving boldly into the next phase 2018-2021 (NCRI webpage)
CTRad’s new strategic vision 2018-2021
In light of progress made in the past three years, CTRad’s Executive Group put together a mission statement to guide the group’s direction of travel, and devised a five-point strategic vision that builds on success to date and addresses on-going challenges. You can download the two-page brief below:
NCRI launches new five year strategy and re-designed website
The NCRI partnership launches new five-year strategy to accelerate progress in cancer research and CTRad is identified as its flagship initiative. Read about this and the PATHOS case study in the new strategy available below.
Landmark paper published by CTRad Working Group
A CTRad Working Group has published a landmark paper in Nature Reviews Clinical Oncology setting out consensus recommendations to increase the number of novel drugs being successfully used in combination with radiotherapy to improve clinical outcomes for patients with cancer.
Now published: CTRad review of molecular radiotherapy research in the UK
CTRad has published its review of molecular radiotherapy (MRT) research in the UK. MRT has considerable potential to benefit patients, and could provide further scope for improved patient outcomes, however research in MRT has lagged behind that of other cancer therapies. To help assess the needs and opportunities in UK MRT research, CTRad consulted with the UK MRT community to ascertain the range of research activity and the barriers preventing progress. The feedback identified opportunities for improvement as well as a number of barriers and challenges. This report identifies three strategic priorities and provides a number of recommendations for each that will promote progress in MRT research.
» CTRad: identifying opportunities to promote progress in molecular radiotherapy research in the UK, June 2016 (PDF) (NCRI webpage)